Associated tags: FDA, GRB2, Acute myeloid leukemia, Bone marrow, IND, RNA interference, STAT3, Lymphoma, Holding, Pharmaceutical industry, Patient, AML
Locations: GA, BELLAIRE, TX, US, UNITED STATES
The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire five years from the date of issuance.
Key Points:
- The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire five years from the date of issuance.
- H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
- The gross proceeds to Bio-Path from the offering were approximately $1.2 million, before deducting the placement agent’s fees and other offering expenses payable by Bio-Path.
- Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
The offering is expected to close on or about April 19, 2024, subject to the satisfaction of customary closing conditions.
Key Points:
- The offering is expected to close on or about April 19, 2024, subject to the satisfaction of customary closing conditions.
- Immediately prior to the registered direct offering and the concurrent private placement, the number of outstanding shares of common stock of the Company was 1,190,306.
- Immediately following the closing of the registered direct offering and the concurrent private placement, the number of outstanding shares of common stock of the Company will be 1,565,306.
- The gross proceeds to Bio-Path from the offering are expected to be approximately $1.2 million, before deducting the placement agent’s fees and other offering expenses payable by Bio-Path.
FDA,
University,
RNA interference,
Hospital,
Hope,
Safety,
Survival,
Weill Cornell Medicine,
Holding,
AML,
Salvage therapy,
Cornell University,
D.O,
MD Anderson Cancer Center,
Patient,
Clinical,
Medicine,
Acute myeloid leukemia,
Messenger,
Clinical trial,
Scripps Health,
BH3,
Cancer,
Pharmaceutical industry By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
Key Points:
- By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
- The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days.
- The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients.
- Gail J. Roboz, M.D., is the National Principal Investigator for the Phase 1/1b trial.
Bio-Path has expanded its intellectual property portfolio by filing patent applications that are applicable to its technology and business strategy.
Key Points:
- Bio-Path has expanded its intellectual property portfolio by filing patent applications that are applicable to its technology and business strategy.
- Bio-Path’s patent portfolio currently includes five issued patents in the U.S. and 54 issued patents in foreign jurisdictions, providing protection in 21 countries.
- On this basis, Bio-Path has one additional patent application allowed in the U.S. and five additional patent applications allowed in foreign jurisdictions, for a total of six additional patent grants expected this year.
- Further, the Company has five pending patent applications in the U.S. and 46 pending patent applications in key foreign jurisdictions across six families of applications, for a total of 51 pending applications.
Toxicity,
Obesity,
Drug discovery,
Chronic lymphocytic leukemia,
Survival,
CLL,
AML,
Fast track (FDA),
Insulin,
Patient,
New York Medical College,
Biomarker,
Cancer,
Leukemia,
IND,
University,
Lymphoma,
Pancreatic cancer,
Clinical trial,
Paclitaxel,
Potential,
Breast cancer,
Safety,
RNA interference,
GRB2,
Holding,
Leptin,
Probability,
FDA,
STAT3,
Stage 4,
Food,
Pharmaceutical industry HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024.
Key Points:
- HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024.
- Prexigebersen Phase 2 Clinical Trial – Bio-Path’s Phase 2 clinical trial is treating Acute Myeloid Leukemia (AML) patients.
- Phase 1/1b Clinical Trial in BP1002 in Relapsed/Refractory AML – A Phase 1/1b clinical trial for BP1002 to treat relapsed/refractory AML patients, including venetoclax-resistant patients, is ongoing.
- In January 2024, Bio-Path announced successful completion of the first dose cohort in the Phase 1 clinical trial.
Division,
Research,
AML,
University,
Clinical trial,
Chronic lymphocytic leukemia,
CLL,
Holding,
MD Anderson Cancer Center,
Patient,
D.O,
Lymphoma,
KOL,
Pharmaceutical industry “2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.
Key Points:
- “2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.
- As of December 31, 2023, the Company had cash of $1.1 million, compared to $10.4 million as of December 31, 2022.
- Net cash provided by financing activities for the year ended December 31, 2023 was $2.2 million.
- ET to review these full-year 2023 financial results and to provide a general update on the Company.
ET to report financial results for the fourth quarter and full year ended December 31, 2023 and to provide a business overview.
Key Points:
- ET to report financial results for the fourth quarter and full year ended December 31, 2023 and to provide a business overview.
- To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time.
- A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com .
- An archived webcast will be available on the Bio-Path website approximately two hours after the event.
Retrieved on:
Wednesday, February 21, 2024
Annual report,
Cancer,
Holding,
STAT3,
Pandemic,
CUSIP,
COVID-19,
Patent,
Patient,
Intellectual property,
Eastern Time Zone,
Uncertainty,
Security (finance),
Trust,
IND,
RNA interference,
Cell Upon the effectiveness of the reverse stock split, every 20 shares of common stock issued and outstanding as of the effective date will be automatically combined into one share of common stock.
Key Points:
- Upon the effectiveness of the reverse stock split, every 20 shares of common stock issued and outstanding as of the effective date will be automatically combined into one share of common stock.
- No fractional shares of common stock will be issued in connection with the reverse stock split.
- The reverse stock split will not change the par value of the common stock or modify the rights or preferences of the common stock.
- The Company anticipates that the reverse stock split will reduce the number of shares of the Company’s common stock issued and outstanding from 12,352,664 shares to approximately 617,833 shares.
Retrieved on:
Wednesday, January 10, 2024
BH3,
Patient,
Associate,
CLL,
RNA,
RNA interference,
Cancer,
Safety,
University,
AML,
New York Medical College,
Holding High expression of Bcl-2 has been correlated with adverse prognosis for patients diagnosed with relapsed, aggressive non-Hodgkin’s lymphoma.
Key Points:
- High expression of Bcl-2 has been correlated with adverse prognosis for patients diagnosed with relapsed, aggressive non-Hodgkin’s lymphoma.
- In the Phase 1 trial, refractory/relapsed CLL patients, including those who have failed or relapsed from venetoclax-based frontline therapy, as well as refractory/relapsed lymphoma patients, will be treated with BP1002.
- As a result, Bio-Path believes that BP1002 could provide an alternative treatment for venetoclax refractory/relapsed CLL patients.
- The primary objective of the study is to evaluate the safety and tolerability of escalating doses of BP1002.
Retrieved on:
Thursday, December 14, 2023
RNA interference,
Weill Cornell Medicine,
Hospital,
D.O,
Hope,
MD Anderson Cancer Center,
Cornell University,
Holding,
University,
Scripps Health,
Toxicity,
Acute myeloid leukemia,
Patient,
Safety,
Clinical,
Medicine,
AML,
Pharmaceutical industry The first dose cohort consisted of a starting dose of 20 mg/m2, and there were no dose limiting toxicities.
Key Points:
- The first dose cohort consisted of a starting dose of 20 mg/m2, and there were no dose limiting toxicities.
- The approved treatment cycle is two doses per week over four weeks for a total of eight doses administered over twenty-eight days.
- The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients.
- Gail J. Roboz, M.D., is the National Principal Investigator for the Phase 1/1b trial.
